FBT holdings
All 32 positions of First Trust NYSE Arca Biotechnology Index Fund.
Positions
32
Top 10 weight
43.2%
Effective holdings
28.1
1 / sum of squared weights
In stocks
100.0%
In bonds
0.0%
Outside the US
15.1%
Asset mix
Sectors
96% of stocks classifiedCountries
Holdings
| # | Holding | Type | Weight | Value | Shares / par | Country |
|---|---|---|---|---|---|---|
| 1 | CORTCorcept Therapeutics Inc. | Equity | 5.60% | $157M | 1,810,937 | US |
| 2 | NEONeoGenomics, Inc. | Equity | 5.12% | $144M | 9,869,496 | US |
| 3 | VCYTVeracyte, Inc. | Equity | 5.10% | $143M | 2,441,185 | US |
| 4 | BRKRBruker Corporation | Equity | 4.32% | $122M | 2,019,057 | US |
| 5 | ALKERMES PLC | Equity | 4.24% | $119M | 2,275,074 | IE |
| 6 | ILMNIllumina Inc | Equity | 3.92% | $110M | 627,605 | US |
| 7 | KRYSKrystal Biotech, Inc. Common Stock | Equity | 3.87% | $109M | 293,036 | US |
| 8 | NTRANatera, Inc. Common Stock | Equity | 3.79% | $107M | 393,185 | US |
| 9 | AXSMAxsome Therapeutics, Inc | Equity | 3.71% | $104M | 426,122 | US |
| 10 | NBIXNeurocrine Biosciences Inc | Equity | 3.53% | $99M | 588,847 | US |
| 11 | TECHBio-Techne Corp. | Equity | 3.43% | $97M | 1,366,518 | US |
| 12 | ARWRArrowhead Research Corporation | Equity | 3.38% | $95M | 1,165,127 | US |
| 13 | BIIBBiogen Inc. Common Stock | Equity | 3.37% | $95M | 438,784 | US |
| 14 | EXELExelixis Inc | Equity | 3.32% | $93M | 1,714,400 | US |
| 15 | INCYIncyte Genomics Inc | Equity | 3.18% | $90M | 790,013 | US |
| 16 | ARGXargenx SE American Depositary Shares | Equity | 3.13% | $88M | 94,913 | NL |
| 17 | HALOHalozyme Therapeutics, Inc. | Equity | 3.11% | $88M | 1,119,086 | US |
| 18 | VRTXVertex Pharmaceuticals Inc | Equity | 3.07% | $86M | 173,968 | US |
| 19 | RGENRepligen Corp | Equity | 3.07% | $86M | 631,943 | US |
| 20 | BMRNBioMarin Pharmaceuticals Inc | Equity | 2.83% | $80M | 1,391,830 | US |
| 21 | AMGNAmgen Inc | Equity | 2.78% | $78M | 216,227 | US |
| 22 | BNTXBioNTech SE American Depositary Share | Equity | 2.63% | $74M | 794,727 | DE |
| 23 | GMABGenmab A/S ADS | Equity | 2.62% | $74M | 2,686,600 | DK |
| 24 | UTHRUnited Therapeutics Corp | Equity | 2.56% | $72M | 132,748 | US |
| 25 | ALNYAlnylam Pharmaceuticals, Inc. | Equity | 2.52% | $71M | 235,602 | US |
| 26 | ONCBeOne Medicines Ltd. American Depositary Shares | Equity | 2.48% | $70M | 245,095 | CH |
| 27 | GILDGilead Sciences Inc | Equity | 2.45% | $69M | 545,899 | US |
| 28 | ADMAADMA Biologics, Inc. | Equity | 2.33% | $65M | 7,823,567 | US |
| 29 | SRPTSarepta Therapeutics,, Inc. Common Stock | Equity | 2.29% | $64M | 3,583,400 | US |
| 30 | REGNRegeneron Pharmaceuticals Inc | Equity | 2.25% | $63M | 101,350 | US |
| 31 | DREYFUS GOVERNMENT CASH MANAGEMENT FUNDS | Cash | 0.05% | $1.5M | 1,526,391 | US |
| 32 | DAIWA CAPITAL MARKETS AMERICA INC. | Cash | 0.00% | $5K | 4,689 | US |
Find which other funds hold a stock by opening it and choosing "ETFs holding".
Position changes between reports
| Action | Holding | Weight before | Weight after | Shares vs flows | Between reports |
|---|---|---|---|---|---|
| Exit | MRNAModerna Inc | 5.26% | — | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | ARWRARROWHEAD PHARMACEUTICALS INC | — | 3.38% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | NEONEOGENOMICS INC | 2.00% | 5.12% | +60.9% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | ACADAcadia Pharmaceuticals Inc | 2.95% | — | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | VCYTVERACYTE INC | 2.72% | 5.10% | +27.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | ADMAADMA BIOLOGICS INC | — | 2.33% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | BRKRBRUKER CORP | 2.36% | 4.32% | +36.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | UTHRUNITED THERAPEUTICS CORP | 4.36% | 2.56% | −20.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | CORTCORCEPT THERAPEUTICS INC | 3.82% | 5.60% | −15.9% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | GILDGILEAD SCIENCES INC | 4.09% | 2.45% | −18.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | AMGNAMGEN INC | 3.83% | 2.78% | −12.7% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | NTRANATERA INC | 3.03% | 3.79% | +14.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | TECHBIO-TECHNE CORP | 2.83% | 3.43% | +11.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | RGENREPLIGEN CORP | 2.51% | 3.07% | +30.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | ALNYALNYLAM PHARMACEUTICALS INC | 2.95% | 2.52% | +16.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | AXSMAXSOME THERAPEUTICS INC | 3.89% | 3.71% | −18.4% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | GMABGENMAB A/S | 2.78% | 2.62% | +14.0% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | ALKERMES PLC | 4.24% | 4.24% | −16.4% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | EXASExact Sciences Corp | 5.15% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | AXSMAxsome Therapeutics Inc. | — | 3.89% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | WATWaters Corp | 3.39% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | MTDMettler-Toledo International I | 3.24% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | TECHBio-Techne Corp | — | 2.83% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | CORTCorcept Therapeutics Inc. | 1.39% | 3.82% | +126.5% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | MRNAModerna Inc | 3.25% | 5.26% | −10.2% | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | NEONeogenomics Inc | — | 2.00% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | BRKRBruker Corporation | 3.95% | 2.36% | −25.6% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | Alkermes PLC | 2.65% | 4.24% | +20.9% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | ILMNIllumina Inc | 4.13% | 3.10% | −23.6% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | GILDGilead Sciences Inc. | 3.10% | 4.09% | +11.2% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | ACADAcadia Pharmaceuticals Inc | 3.94% | 2.95% | −14.0% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | NTRANATERA INC | 4.00% | 3.03% | −17.0% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | REGNRegeneron Pharmaceuticals, Inc. | 4.04% | 3.45% | −18.6% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | KRYSKrystal Biotech Inc | 4.02% | 3.51% | −20.3% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | BNTXBioNTech SE | 2.76% | 3.16% | +17.4% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | ALNYAlnylam Pharmaceuticals Inc. | 2.55% | 2.95% | +32.7% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | NBIXNeurocrine Biosciences Inc | 3.07% | 3.45% | +15.6% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | ARGXArgenx SE | 3.12% | 3.29% | +16.1% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | BIIBBiogen Inc | 3.55% | 3.47% | −10.3% | Dec 31, 2025 → Mar 31, 2026 SEC |
Share-count changes are measured after removing what creations and redemptions explain.
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.